Press Releases

Date Title and Summary Additional Formats
Toggle Summary NOVELOS THERAPEUTICS SUCCESSFULLY COMPLETES FIRST COHORT IN PHASE 1b SOLID TUMOR TRIAL WITH I-131-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC
NOVELOS THERAPEUTICS SUCCESSFULLY COMPLETES FIRST COHORT IN PHASE 1b SOLID TUMOR TRIAL WITH I-131-CLR1404 (HOT) CANCER-TARGETED MOLECULAR RADIOTHERAPEUTIC First Patient Enrolled in Second Cohort, Additional Clinical Results Expected in Q3 2012 Expects to Begin Phase 2 Proof-of-Concept Trials in Q1
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF FIRST COHORT IN LUNG CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF FIRST COHORT IN LUNG CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Demonstrates Positive Initial Imaging Results; Additional Clinical Results Expected by mid-2012 MADISON, WI, April 24,
View HTML
Toggle Summary NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT THREE POSTERS AT 2012 AACR ANNUAL MEETING
NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS PRESENT THREE POSTERS AT 2012 AACR ANNUAL MEETING Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described MADISON, WI, April 3, 2012 – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN BRAIN CANCER TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Expects Initial Imaging Results in the Second Quarter of 2012 MADISON, WI, March 15, 2012 – Novelos Therapeutics, Inc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS HAVE THREE ABSTRACTS ACCEPTED FOR PRESENTATION AT 2012 AACR ANNUAL MEETING
NOVELOS THERAPEUTICS AND ACADEMIC COLLABORATORS HAVE THREE ABSTRACTS ACCEPTED FOR PRESENTATION AT 2012 AACR ANNUAL MEETING Broad-Spectrum, Cancer-Targeting Therapeutic and Diagnostic Agents Described MADISON, WI, March 1, 2012 – Novelos Therapeutics, Inc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS PRICES $5.9 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS PRICES $5.9 MILLION PUBLIC OFFERING MADISON, WI, December 1, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES JUDGMENT IN ITS FAVOR AND DISMISSAL OF STATE LAW COUNTERCLAIMS
NOVELOS THERAPEUTICS ANNOUNCES JUDGMENT IN ITS FAVOR AND DISMISSAL OF STATE LAW COUNTERCLAIMS MADISON, WI, October 19, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on October 17,
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT RODMAN & RENSHAW 13th ANNUAL HEALTHCARE CONFERENCE ON SEPTEMBER 12
NOVELOS THERAPEUTICS TO PRESENT AT RODMAN & RENSHAW 13th ANNUAL HEALTHCARE CONFERENCE ON SEPTEMBER 12 MADISON, WI, September 6, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S.
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES DISMISSAL OF PUTATIVE FEDERAL SECURITIES CLASS ACTION LAWSUIT
NOVELOS THERAPEUTICS ANNOUNCES DISMISSAL OF PUTATIVE FEDERAL SECURITIES CLASS ACTION LAWSUIT MADISON, WI, June 28, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011,
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT THE 5th LIPPERT/HEILSHORN LIFE SCIENCES & MEDICAL TECHNOLOGIES VIRTUAL CONFERENCE ON JUNE 16
NOVELOS THERAPEUTICS TO PRESENT AT THE 5th LIPPERT/HEILSHORN LIFE SCIENCES & MEDICAL TECHNOLOGIES VIRTUAL CONFERENCE ON JUNE 16 MADISON, WI, June 13, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today
View HTML